{"symbol":"REGN","fiscalQuarter":"Q2-2014","reportDate":"2014-08-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2014","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.38%","keyNumbers":[{"metric":"EPS","actual":"$2.47","expected":"N/A","surprise":"+6.01%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite not providing revenue figures.","They highlighted ongoing investments in research and development as a priority."],"summary":"Overall, management conveyed a positive outlook on earnings performance. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a solid EPS performance, which contributed to a 2.38% increase in the stock price. The positive surprise in EPS indicates that the company is managing its costs effectively. However, the lack of revenue data and guidance leaves some uncertainty about future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2014 earnings: EPS beat expectations. Stock up 2.38%. Full breakdown."}}